Lab Sciences
Top stories summarized by our editors
7/25/2017

A round of Series C financing led by Tiger Partners and Forbion Capital Partners pulled in $30 million for Exosome Diagnostics. The proceeds will be used for a rapid commercial expansion of the ExoDx Prostate (IntelliScore) test, as well as to commercialize oncological diagnostics, develop tests for other applications, conduct investigations into new technologies and expand the company's companion diagnostics and instrumentation arms.

7/25/2017

Researchers found that IsoPSA, a blood-based test to measure all prostate-specific antigen isoforms, reduced false-positive biopsies by 48% and outperformed PSA in predicting overall prostate cancer risk and the risk of clinically significant cancer. The authors noted that adjusting the results for demographic parameters such as age and race could improve IsoPSA's performance.

7/24/2017

A case study presented at a conference of the International AIDS Society described a 9-year-old South African child born with HIV who achieved remission for 8.5 years despite discontinuing antiretroviral treatment in infancy. The findings suggest that brief HIV treatment for affected children in infancy may in some cases allow long-term remission and prevention of some HIV-related health risks but more studies are needed, said National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci.

Full Story:
CNN, BBC, The Guardian (London)
7/24/2017

An analysis of data from 645 US hospitals found a 20% reduction in blood use for 134 diagnoses, according to a report from Premier. Patient blood management programs were associated with the decreased transfusion rates.

Full Story:
Healthcare Dive
7/24/2017

Intensified surveillance in Wisconsin for mosquitoes that can carry the Zika virus has resulted in the discovery of Aedes albopictus in the state, according to investigators with the Upper Midwestern Center of Excellence in Vector Borne Diseases. The center has increased its monitoring efforts through a CDC grant.

More Summaries:
CDC
7/21/2017

Amgen's biologics license application for Aimovig, or erenumab, to prevent migraine in patients who experience at least four migraines a month, has been accepted for review by the FDA with an expected action date of May 17, 2018. Amgen and Novartis will jointly commercialize the drug.

More Summaries:
Amgen, FDA, migraine, Novartis, Aimovig
7/21/2017

The World Health Organization has recommended the investigative RTS,S malaria vaccine for testing in a pilot program in Ghana, Kenya and Malawi. The vaccine is being developed by GlaxoSmithKline.

7/20/2017

Moleculin Biotech and the MD Anderson Cancer Center in Houston have signed a licensing deal to test Annamycin as a treatment for relapsed or refractory acute myeloid leukemia. New patent applications will be filed by Moleculin before launching plans for future clinical trials.

7/20/2017

The World Health Organization will observe World Hepatitis Day on July 28 with a focus on its goal of eliminating viral hepatitis. The WHO will publish reports on challenges and progress in the 28 nations that account for 70% of the worldwide hepatitis burden, and the agency says its 2030 goal of treating 80% of all eligible patients with hepatitis C and B is not overly ambitious.

Full Story:
Pakistan Today
More Summaries:
World Health Organization
7/20/2017

The government of Australia has donated $377,000 to the World Health Organization for dengue fever prevention, management and eradication programs in Sri Lanka. Australia has also allocated $795,000 for collaborative research by the Sri Lankan Health Ministry and Australia's Monash University on the use of Wolbachia bacteria to limit spread of the virus by mosquitoes.